Mirum's M&A Playbook: Betting Big on a Diversified Rare Disease Portfolio
Mirum Pharmaceuticals charts a distinct course in the rare disease biotech landscape, leveraging strategic acquisitions to build a broad, sustainable pipeline while navigating a complex regulatory environment.